Print

Alexion Pharmaceuticals Inc. (ALXN) Release: New Data Highlighting Long-Term Efficacy and Safety Outcomes of PNH Patients Treated With Soliris® Reported at American Society of Hematology Annual Meeting  
12/10/2012 9:46:19 AM

CHESHIRE, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced the presentation of new data demonstrating the long-term benefits of SolirisĀ® (eculizumab) in patients with paroxysmal nocturnal hemoglobinuria (PNH), a debilitating, ultra-rare and life-threatening blood disorder characterized by complement-mediated hemolysis (destruction of red blood cells). Data including the clinical benefits of Soliris in the treatment of patients with PNH and atypical hemolytic uremic syndrome (aHUS) were presented at the 54th Annual Meeting of the American Society of Hematology (ASH) in Atlanta:
//-->